National Institute of Neurological Disorders and Stroke; Notice of Meeting, 4578-4579 [2015-01484]
Download as PDF
4578
Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
Joint Meeting of the Dermatologic and
Ophthalmic Drugs Advisory Committee
and Ophthalmic Devices Panel of the
Medical Devices Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
mstockstill on DSK4VPTVN1PROD with NOTICES
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees: Dermatologic and
Ophthalmic Drugs Advisory Committee and
Ophthalmic Devices Panel of the Medical
Devices Advisory Committee.
General Function of the Committee: To
provide advice and recommendations to the
Agency on FDA’s regulatory issues.
Date and Time: The meeting will be held
on February 24, 2015, from 8 a.m. to 5 p.m.
Location: FDA White Oak Campus, 10903
New Hampshire Ave., Bldg. 31 Conference
Center, the Great Room (Rm. 1503), Silver
Spring, MD 20993–0002. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability, visitor
parking, and transportation may be accessed
at: https://www.fda.gov/AdvisoryCommittees/
AboutAdvisoryCommittees/ucm408555.htm.
Contact Person: Moon Hee V. Choi, Center
for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2147, Silver Spring, MD
20993–0002, 301–796–9001, FAX: 301–847–
8533, email: DODAC@fda.hhs.gov, or FDA
Advisory Committee Information Line, 1–
800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly enough
to provide timely notice. Therefore, you
should always check the Agency’s Web site
at https://www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting link,
or call the advisory committee information
line to learn about possible modifications
before coming to the meeting.
Agenda: The committees will discuss new
drug application (NDA) 203324, for
riboflavin ophthalmic solutions with UV–A
irradiation, submitted by Avedro, Inc. The
combination products are used in corneal
collagen cross-linking and proposed to be
indicated for the treatment of progressive
keratoconus or corneal ectasia following
refractive surgery.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
VerDate Sep<11>2014
16:41 Jan 27, 2015
Jkt 235001
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee meeting link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
February 9, 2015. Oral presentations from the
public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
individuals interested in making formal oral
presentations should notify the contact
person and submit a brief statement of the
general nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and an
indication of the approximate time requested
to make their presentation on or before
January 30, 2015. Time allotted for each
presentation may be limited. If the number of
registrants requesting to speak is greater than
can be reasonably accommodated during the
scheduled open public hearing session, FDA
may conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 2, 2015.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Moon Hee
V. Choi at least 7 days in advance of the
meeting.
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/ucm111462.htm
for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: January 23, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2015–01534 Filed 1–27–15; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Muscular Dystrophy Coordinating
Committee (MDCC).
The meeting will be open to the
public and accessible by live webcast.
Name of Committee: Muscular Dystrophy
Coordinating Committee.
Type of meeting: Open Meeting.
Date: March 17, 2015.
Time: 8:30 a.m. to 4:30 p.m. *Eastern
Time*—Approximate end time.
Agenda: The Muscular Dystrophy
Coordinating Committee (MDCC) is
mandated by the MD–CARE Act to ‘‘develop
a plan for conducting and supporting
research and education on muscular
dystrophy through the national research
institutes, and will periodically review and
revise the plan.’’ The Committee will discuss
the draft 2015 Action Plan for the Muscular
Dystrophies at this meeting. Prior to the
meeting, an agenda will be posted to the
MDCC meeting registration Web site:
https://meetings.ninds.nih.gov/meetings/
MDCC/.
Registration: To register, please go to:
https://meetings.ninds.nih.gov/meetings/
MDCC/.
Webcast Live: For those not able to attend
in person, this meeting will be webcast at:
https://videocast.nih.gov/.
Place: Natcher Conference Center (Building
45), Conference Room D, National Institutes
of Health, 9000 Rockville Pike, Bethesda,
Maryland 20892.
Contact Person: Glen H. Nuckolls, Ph.D.,
Executive Secretary, Muscular Dystrophy
Coordinating Committee, National Institute
of Neurological Disorders and Stroke, NIH,
6001 Executive Boulevard, NSC 2203,
Bethesda, MD 20892, (301) 496–5739,
glen.nuckolls@ninds.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
E:\FR\FM\28JAN1.SGM
28JAN1
Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices
business or professional affiliation of the
interested person.
Attendance is limited to seating space
available. Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other reasonable
accommodations, should inform the Contact
Person listed below in advance of the
meeting.
All visitors must go through a security
check at the NIH main campus to receive a
visitor’s badge. A government issued photo
ID is required. Further information can be
found at the registration Web site: https://
meetings.ninds.nih.gov/meetings/MDCC/.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: January 22, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–01484 Filed 1–27–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cellular
Aspects of Diabetes and Obesity.
Date: February 19, 2015.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814,
(Telephone Conference Call).
Contact Person: Reed A Graves, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6166,
MSC 7892, Bethesda, MD 20892, (301) 402–
6297, gravesr@csr.nih.gov.
VerDate Sep<11>2014
16:41 Jan 27, 2015
Jkt 235001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Thrombosis and Vascular.
Date: February 19, 2015.
Time: 4:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Luis Espinoza, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4140,
MSC 7814, Bethesda, MD 20892, 301–435–
0952, espinozala@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Clinical and
Translational Imaging Applications.
Date: February 20, 2015.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Eileen W Bradley, DSC,
Chief, SBIB IRG, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5100, MSC 7854, Bethesda, MD
20892, (301) 435–1179, bradleye@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Molecular
Targets for Cancer Intervention.
Date: February 23, 2015.
Time: 7:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Careen K Tang-Toth,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301) 435–
3504, tothct@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Developmental Therapeutics Study
Section.
Date: February 23–24, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel at Pentagon City,
1250 South Hayes Street, Arlington, VA
22202.
Contact Person: Sharon K Gubanich, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301) 408–
9512, gubanics@csr.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Motor Function, Speech and
Rehabilitation Study Section.
Date: February 23–24, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: El Tropicano Riverwalk Hotel, 110
Lexington Ave, San Antonio, TX 78205.
Contact Person: Biao Tian, Ph.D., Scientific
Review Officer, Center for Scientific Review,
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
4579
National Institutes of Health, 6701 Rockledge
Drive, Room 3166, MSC 7848, Bethesda, MD
20892, 301–402–4411, tianbi@csr.nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Tumor Microenvironment Study Section.
Date: February 23–24, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel, 1700 Tysons
Boulevard, McLean, VA 22102.
Contact Person: Angela Y Ng, Ph.D., MBA,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6200,
MSC 7804, Bethesda, MD 20892, 301–435–
1715, ngan@mail.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Vascular Cell and Molecular Biology Study
Section.
Date: February 23–24, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Guest Suites Santa
Monica, 1707 Fourth Street, Santa Monica,
CA 90401.
Contact Person: Larry Pinkus, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Diseases and Pathophysiology of the
Visual System Study Section.
Date: February 23–24, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Long Beach, 333 East
Ocean Boulevard, Long Beach, CA 90802.
Contact Person: Nataliya Gordiyenko,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5202,
MSC 7846, Bethesda, MD 20892, 301–435–
1265, gordiyenkon@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Services Organization and Delivery
Study Section.
Date: February 23–24, 2015.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Jacinta Bronte-Tinkew,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164,
MSC 7770, Bethesda, MD 20892, (301) 806–
0009, brontetinkewjm@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Cellular and Molecular
Biology of Neurodegeneration Study Section.
Date: February 23–24, 2015.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\28JAN1.SGM
28JAN1
Agencies
[Federal Register Volume 80, Number 18 (Wednesday, January 28, 2015)]
[Notices]
[Pages 4578-4579]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01484]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Muscular Dystrophy Coordinating Committee (MDCC).
The meeting will be open to the public and accessible by live
webcast.
Name of Committee: Muscular Dystrophy Coordinating Committee.
Type of meeting: Open Meeting.
Date: March 17, 2015.
Time: 8:30 a.m. to 4:30 p.m. *Eastern Time*--Approximate end
time.
Agenda: The Muscular Dystrophy Coordinating Committee (MDCC) is
mandated by the MD-CARE Act to ``develop a plan for conducting and
supporting research and education on muscular dystrophy through the
national research institutes, and will periodically review and
revise the plan.'' The Committee will discuss the draft 2015 Action
Plan for the Muscular Dystrophies at this meeting. Prior to the
meeting, an agenda will be posted to the MDCC meeting registration
Web site: https://meetings.ninds.nih.gov/meetings/MDCC/.
Registration: To register, please go to: https://meetings.ninds.nih.gov/meetings/MDCC/.
Webcast Live: For those not able to attend in person, this
meeting will be webcast at: https://videocast.nih.gov/.
Place: Natcher Conference Center (Building 45), Conference Room
D, National Institutes of Health, 9000 Rockville Pike, Bethesda,
Maryland 20892.
Contact Person: Glen H. Nuckolls, Ph.D., Executive Secretary,
Muscular Dystrophy Coordinating Committee, National Institute of
Neurological Disorders and Stroke, NIH, 6001 Executive Boulevard,
NSC 2203, Bethesda, MD 20892, (301) 496-5739,
glen.nuckolls@ninds.nih.gov.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the
[[Page 4579]]
business or professional affiliation of the interested person.
Attendance is limited to seating space available. Individuals
who plan to attend and need special assistance, such as sign
language interpretation or other reasonable accommodations, should
inform the Contact Person listed below in advance of the meeting.
All visitors must go through a security check at the NIH main
campus to receive a visitor's badge. A government issued photo ID is
required. Further information can be found at the registration Web
site: https://meetings.ninds.nih.gov/meetings/MDCC/.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: January 22, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-01484 Filed 1-27-15; 8:45 am]
BILLING CODE 4140-01-P